Clinical Trial Update: Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT). [Phase 2]

View source ↗

Summary

A completed Phase 2 safety study evaluating a vasopressin V2 receptor antagonist in patients with severe chronic heart failure (AQUAVIT), sponsored by Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Vasopressin V2 receptor antagonist

Snippet

Sponsor: Sanofi | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED